Investor News.

Investor News View all

Doseology Appoints Maryam Marissen as CEO to Prepare for Next Growth Stage
Doseology Completes Development and Test Marketing of Adaptogenic Mushroom Product Line
Investor Year End Update
Doseology Prepares to Expand Mushroom Production by Hiring Dr. Wellman-Labadie to Oversee Planned Research and Development Laboratory
Doseology Prepares for Growth Phase in Psychedelic-Focused Mental Health Market, Completes Dealer’s License Application
Doseology Set to Trade CSE: MOOD
Doseology Receives Receipt for Final Prospectus and Amounts Listing on the CSE : MOOD
Doseology Raises $4,451,568 and Files Preliminary Non-offering Prospectus.